Literature DB >> 27601292

Voriconazole metabolism is influenced by severe inflammation: a prospective study.

Anette Veringa1, Mendy Ter Avest1, Lambert F R Span2, Edwin R van den Heuvel3, Daan J Touw1, Jan G Zijlstra4, Jos G W Kosterink1,5, Tjip S van der Werf6,7, Jan-Willem C Alffenaar8.   

Abstract

BACKGROUND: During an infection or inflammation, several drug-metabolizing enzymes in the liver are down-regulated, including cytochrome P450 iso-enzymes. Since voriconazole is extensively metabolized by cytochrome P450 iso-enzymes, the metabolism of voriconazole can be influenced during inflammation via reduced clearance of the drug, resulting in higher voriconazole trough concentrations.
OBJECTIVE: To investigate prospectively the influence of inflammation on voriconazole metabolism and voriconazole trough concentrations.
METHODS: A prospective observational study was performed at the University Medical Center Groningen. Patients were eligible for inclusion if they were ≥18 years old and treated with voriconazole. Voriconazole and voriconazole-N-oxide concentrations were determined in discarded blood samples. To determine the degree of inflammation, C-reactive protein (CRP) concentrations were used. Subsequently, a longitudinal data analysis was performed to assess the effect of inflammation on the metabolic ratio and voriconazole trough concentration.
RESULTS: Thirty-four patients were included. In total 489 voriconazole trough concentrations were included in the longitudinal data analysis. This analysis showed that inflammation, reflected by CRP concentrations, significantly influenced the metabolic ratio, voriconazole trough concentration and voriconazole-N-oxide concentration (all P < 0.001), when corrected for other factors that could influence voriconazole metabolism. The metabolic ratio was decreased by 0.99229N and the voriconazole-N-oxide concentration by 0.99775N, while the voriconazole trough concentration was increased by 1.005321N, where N is the difference in CRP units (in mg/L).
CONCLUSIONS: This study shows that voriconazole metabolism is decreased during inflammation, resulting in higher voriconazole trough concentrations. Therefore, frequent monitoring of voriconazole serum concentrations is recommended during and following severe inflammation.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27601292     DOI: 10.1093/jac/dkw349

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

1.  Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis.

Authors:  Sara Blanco-Dorado; Ana Teresa Marques Afonso; Enrique José Bandín-Vilar; Ignacio Novo-Veleiro; Fernando Ferrón Vidán; Ana Latorre-Pellicer; Olalla Maroñas Amigo; Anxo Fernández-Ferreiro; María Jesús Lamas
Journal:  Br J Clin Pharmacol       Date:  2018-12-09       Impact factor: 4.335

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Authors:  B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh
Journal:  Clin Pharmacol Ther       Date:  2017-04-18       Impact factor: 6.875

3.  Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China.

Authors:  Jing Guo; Bing-Kun Li; Tian-Min Li; Fang-Lin Wei; Yu-Jiao Fu; Yan-Qing Zheng; Kai-Su Pan; Chun-Yang Huang; Cun-Wei Cao
Journal:  Mycopathologia       Date:  2019-08-31       Impact factor: 2.574

4.  Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms.

Authors:  Guangting Zeng; Linlin Wang; Lihong Shi; Huilan Li; Miaomiao Zhu; Jia Luo; Zanling Zhang
Journal:  Eur J Clin Pharmacol       Date:  2020-01-14       Impact factor: 2.953

5.  High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.

Authors:  L Bernal-Martínez; L Alcazar Fuoli; B Miguel-Revilla; A Carvalho; M S Cuétara Garcia; J Garcia-Rodriguez; C Cunha; E Gómez-García de la Pedrosa; A Gomez-Lopez
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 6.  Voriconazole: A Review of Population Pharmacokinetic Analyses.

Authors:  Changcheng Shi; Yubo Xiao; Yong Mao; Jing Wu; Nengming Lin
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

7.  Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.

Authors:  Xiao-Bin Lin; Zi-Wei Li; Miao Yan; Bi-Kui Zhang; Wu Liang; Feng Wang; Ping Xu; Da-Xiong Xiang; Xu-Biao Xie; Shao-Jie Yu; Gong-Bin Lan; Feng-Hua Peng
Journal:  Br J Clin Pharmacol       Date:  2018-05-06       Impact factor: 4.335

8.  Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.

Authors:  Lena Cerruti; Nathalie Bleyzac; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

9.  Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?

Authors:  Matthew A Miller; Yee Ming Lee
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16

10.  Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data.

Authors:  Léa Bolcato; Charles Khouri; Anette Veringa; Jan Willem C Alffenaar; Takahiro Yamada; Takafumi Naito; Fabien Lamoureux; Xavier Fonrose; Françoise Stanke-Labesque; Elodie Gautier-Veyret
Journal:  J Clin Med       Date:  2021-05-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.